Introduction
ternary complexes, aligning the two proenzymes in a way that exploits their low intrinsic activity and thereby favors a mutual activation process (13) . The net result of this process is the efficient and localized generation of active uPA and plasmin on the cell surface.
Although many studies have documented the central role of uPA-mediated cell-surface plasminogen activation requiring uPAR, recent studies in uPAR-deficient mice have demonstrated the existence of additional, uPAR-independent pathways of uPA-mediated plasminogen activation, in the context of both physiological cell migration and fibrin dissolution (14, 15) . uPAR and uPA are overexpressed with remarkable consistency in malignant human tumors, including monocytic and myelogenous leukemias (16, 17) , cancers of the colon (18) , breast (19) , bladder (20) , thyroid (21) , liver (22) , pleura (23) , lung (24) , pancreas (25) , ovaries (26) , and the head and neck (27) . Extensive in situ hybridization and immunohistochemical studies of various human tumor types have demonstrated that cancer cells typically express uPAR, while pro-uPA may be expressed by either the cancer cells or by adjacent stromal cells (18, 28, 29) .
Plasminogen activation by uPA is regulated by two physiological inhibitors, plasminogen activator inhibitors-1 and 2 (PAI-1 and PAI-2) (30) (31) (32) , each forming a 1:1 complex with uPA.
Plasmin generated by the cell surface plasminogen activation system is relatively protected from its primary physiological inhibitor α 2 -antiplasmin (11, 33, 34) . Unlike uPA, plasmin is a relatively non-specific protease, capable of degrading fibrin and several other glycoproteins and proteoglycans of the extracellular matrix (35) . Therefore, cell surface plasminogen activation facilitates invasion and metastasis of tumor cells by dissolution of restraining tissue barriers. In addition, cell surface plasminogen activation may facilitate matrix degradation through the by guest on http://www.jbc.org/ Downloaded from activation of latent matrix metalloproteinases (MMP) (36) . Plasmin can also activate growth factors, such as transforming growth factor-ß, which may further modulate stromal interactions in the expression of enzymes and tumor neo-angiogenesis (37) .
Another protein that requires cell surface proteolytic activation is anthrax toxin. This three-component toxin consists of protective antigen (PrAg, 83 kDa), lethal factor (LF, 90 kDa) and edema factor (EF, 90 kDa) (38) (39) (40) . PrAg binds to an unidentified cell surface receptor and is cleaved at the sequence, 164 RKKR 167 , by a cell-surface, furin-like protease (41, 42) . This cleavage is absolutely required for the subsequent steps in toxin action. The C-terminal 63-kDa fragment (PrAg63) remains bound to receptor, associates to form a heptamer, and binds and internalizes LF and EF (40, (43) (44) (45) . LF kills animals (46, 47) and lyses mouse macrophages (48, 49) , probably due to the proteolytic cleavage of mitogen-activated protein kinase kinases (50, 51) . EF damages cells due to its intracellular adenylate cyclase activity (52) . A potent PrAgdependent cytotoxin, FP59, created by fusing LF amino acids (aa) 1-254 to the ADPribosylation domain of Pseudomonas exotoxin A can kill any cell having receptors for PrAg and the ability to activate PrAg by cleavage at aa 164-167 (53, 54) .
The unique requirement that PrAg be activated on the target cell surface provides an opportunity to re-engineer this protein to make its activation dependent on the tumor cell surface urokinase plasminogen activation system. Our previous work showed that PrAg can be made specific for MMP-expressing cells by replacing the 164 RKKR 167 furin site with sequences preferentially cleaved by MMPs (55) . In this report we extended this approach to exploit the localized activity of the uPA protease on tumor cells. uPA and tPA possess an extremely high degree of structural similarity (56, 57) , share the same primary physiological substrate (plasminogen) and inhibitors (PAI-1 and PAI-2) (58), and exhibit restricted substrate specificity.
by guest on http://www.jbc.org/ Downloaded from encoding CPGRVVGG and S 168 -P 176 , and reverse primer R2, ACGTTTATCTCTTATTAAAAT, annealing to the sequence encoding I 589 -R 595 , to amplify a mutagenic fragment "M1". We used a phosphorylated mutagenic primer H2, pGGAAGTGGAAGATCAGCAAGTACAAGTGCTGGACCTACGGTTCCAG, encoding GSGRSA and S 168 -P 176 , and reverse primer R2, to amplify a mutagenic fragment "M2". We used a phosphorylated mutagenic primer H3, pGGAAGTGGAAAATCAGCAAGTACAAGTGCTGGACCTACGGTTCCAG, encoding GSGKSA and S 168 -P 176 , and reverse primer R2, to amplify a mutagenic fragment "M3". We used a phosphorylated mutagenic primer H4, pCAGAGAGGAAGATCAGCAAGTACAAGTGCTGGACCTACGGTTCCAG, encoding QRGRSA and S 168 -P 176 , and reverse primer R2, to amplify a mutagenic fragment "M4". Primers F and R2 were used to amplify the ligated products of N + M1, N + M2, N + M3, and N + M4, respectively, resulting in the mutagenized fragments U1, U2, U3, and U4 in which the coding sequence for the furin site (RKKR 167 ) is replaced by uPA or tPA substrate sequence. The 670-bp HindIII/PstI fragments from the digests of U1, U2, U3, and U4 were cloned between the HindIII and PstI sites of pYS5. The resulting mutated PrAg proteins were accordingly named PrAg -U1, PrAg -U2, PrAg -U3, and PrAg -U4. We also constructed a mutated PrAg protein, PrAg -U7, in which RKKR 167 is replaced by the sequence PGG. This protein is expected to be resistant to all cell surface proteases. DNA sequencing analyses confirmed the sequences of the mutated PrAg constructs.
Expression and purification of PrAg proteins. Plasmids encoding the constructs described above were transformed into the non-virulent strain Bacillus anthracis UM23C1-1, and transformants were grown in FA medium (62) with 20 µg/ml of kanamycin for 16 h at 37 o C.
The mutated PrAg proteins were concentrated from the culture supernatants and purified by chromatography on a MonoQ column (Amersham Pharmacia Biotech, Piscataway, NJ) by the methods described previously (63) .
In vitro cleavage of PrAg proteins by uPA, tPA, and furin. lysates and equal volumes of the conditioned media were separated by PAGE using 4-20% gradient Tris-glycine gels (Novex). Western blotting was performed as described above to detect pro-uPA and PrAg -U2 and their cleavage products by using the monoclonal antibody against human uPA B-chain (#394) and anti-PrAg polyclonal antibody (#5308).
Cytotoxicity assay in a co-culture system. A co-culture model like that described previously (55) was employed to determine whether PrAg -U2 killed uPAR-overexpressing tumor cells without affecting bystander, uPAR non-expressing cells. Briefly, HeLa and 293 cells were co-cultured in separate compartments of 8-chamber slides. With the partitions removed, the culture slides were incubated for 6 h with native PrAg or PrAg -U2 (each 300 ng/ml) combined with FP59 (50 ng/ml) in serum-free DMEM containing 100 ng/ml pro-uPA and 1 µg/ml Glu-plasminogen. After 48 h, the partitions were replaced and MTT-containing medium was added to each chamber to assess cell viability, as described above.
by guest on http://www.jbc.org/
Downloaded from

Results
Directing uPA-and tPA-specific proteolysis to anthrax PrAg. The furin cleavage site, 164 RKKR 167 , is located in a surface-exposed, flexible loop of PrAg composed of residues 162 to 175 (64) . We constructed mutated PrAg proteins in which this sequence is replaced by sequences that are preferred uPA or tPA substrates (Table I ). The mutated PrAg protein PrAg -U1 contains the sequence PCPGRVVGG, corresponding to positions P5 to P4' in the physiological substrate plasminogen. Protein PrAg -U2 contains the sequence PGSGRSA, which includes the consensus sequence SGRSA, recently identified as the minimized optimum substrate for uPA (59) . Because the sequence SGRSA is cleaved by uPA 1363-fold times more efficiently than the physiological cleavage site present in plasminogen, and because it exhibits a uPA/tPA selectivity of 20 (59), the PrAg -U2 protein is expected to be a specific substrate of uPA. uPA/tPA selectivity of the sequence SGRSA can be further enhanced by placing lysine in the P1 position (59) . Thus, the sequence PGSGKSA, which exhibits a uPA/tPA selectivity of 121 (59), was selected for insertion into the mutated PrAg protein PrAg -U3, which was expected to have an even higher uPA selectivity than PrAg -U2. Ke et al. further showed that the P3 and P4 residues were the primary determinants of the ability of a substrate to discriminate between tPA and uPA. Thus, substitution of both the P4 glycine and the P3 serine of the most labile uPA substrate (GSGRSA) with glutamine and arginine, respectively, decreased the uPA/tPA selectivity by a factor of 1200 and yielded a tPA-selective substrate (59) . Based on that result, we constructed the mutated PrAg protein PrAg -U4 containing the sequence PQRGRSA, so as to produce a tPA-specific substrate. We also constructed a mutated PrAg protein PrAg -U7, in which RKKR 167 was replaced by the sequence PGG. PrAg -U7 is not expected to be cleaved by any known protease, and was used as a control protein in this study. The Table I .
Plasmids encoding these mutated PrAg proteins were constructed by a modified overlap PCR method, cloned into the E. coli-Bacillus shuttle vector pYS5, and expressed in B. anthracis UM23C1-1. The proteins were secreted into the culture supernatants at 20-50 mg/l. The mutated PrAg proteins were concentrated and purified by MonoQ chromatography to one prominent band at the expected molecular mass of 83 kDa, which co-migrated with native PrAg in SDS-PAGE.
Thus, using a production protocol that is now standard in this laboratory, these mutated PrAg proteins could be expressed and purified easily in high yield and purity.
To verify that the mutated PrAg proteins had the expected susceptibility to cleavage by proteases, they were incubated separately with uPA, tPA, and a soluble form of furin. As expected, these mutated PrAg proteins were not cleaved by furin, whereas the native PrAg was cleaved by furin to produce the active PrAg 63 product (Fig. 1A) . The cleavage by furin after the 164 RKKR 167 sequence was confirmed by amino-terminal sequencing of the resulting PrAg63.
The relative susceptibilities of the mutated PrAg proteins to cleavage by uPA and tPA agreed closely with what was predicted from the phage display data used in their design ( Fig. 1 , B and C, Table I ). In particular, uPA cleaved PrAg -U2 very efficiently but was less active on PrAg -U3. Moreover, PrAg -U2 was quite resistant to tPA, with just trace amounts being cleaved even with a 3-h incubation period (Fig. 1C ). PrAg -U3 was even more resistant to tPA, in that no cleavage could be detected at any time point (Fig. 1C) . These results showed the high uPA specificity for these two mutated PrAg proteins. In contrast, PrAg -U4 was a very weak substrate for uPA, but a good substrate for tPA ( amino-terminal sequencing of the resulting PrAg63s. PrAg -U7 and PrAg -U1 were both completely resistant to uPA and tPA (Fig. 1, B and C). Native PrAg was completely resistant to tPA (Fig. 1C) , but was slightly cleaved by uPA at the furin recognition site (Fig. 1B) . When we replaced the furin site with the sequence PGG to produce PrAg -U7, the protein was completely resistant to uPA (Fig. 1B) .
PrAg -U2 and PrAg -U3 selectively kill uPAR-expressing tumor cells. To test the hypothesis that PrAg -U2 and PrAg -U3 would selectively kill uPAR-overexpressing tumor cells, cytotoxicity assays were performed with two human tumor cell lines, cervix adenocarcinoma
HeLa and melanoma A2058. The non-tumor human kidney cell line 293 was used as a control.
Expression of uPAR by these two tumor cell lines but not by 293 cells was reported previously (65) , and was confirmed in this study by performing a pro-uPA binding and processing assay ( Fig. 2A) . In the presence of plasminogen, both HeLa and A2058 cells bound pro-uPA and processed it to the active, two-chain form, as identified by the uPA B-chain antibody. In contrast, the uPAR non-expressing 293 cells showed only a weak binding and failed to convert pro-uPA to two-chain uPA ( Fig. 2A) .
Cytotoxicity of native PrAg and the mutated PrAg proteins to these cells was measured in 96-well plates. In tumor tissues, cancer cells typically overexpress uPAR, while either the cancer cells or the adjacent stromal cells express pro-uPA, which is activated on the cancer cell surface after binding to uPAR. We showed that HeLa and A2058 cells did not express pro-uPA under the current culture condition ("0" lanes in Fig. 2A ). Therefore, in the cytotoxicity assay, 100 ng/ml pro-uPA was added to the tumor cells to mimic the role of pro-uPA secreted in tumor tissues in vivo. We also added 1 µg/ml Glu-plasminogen, because plasminogen is present in high concentration (1.5-2.0 µM) in plasma and interstitial fluids and is required for uPAR-dependent The results showed that the uPAR non-expressing 293 cells were sensitive to native PrAg in a dose-dependent manner, but were completely resistant to killing by all the mutated PrAg proteins (Fig. 2B) . In contrast, the uPAR-expressing HeLa and A2058 cells were highly susceptible to killing by native PrAg, PrAg -U2, and PrAg -U3, were less susceptible to PrAg -U4, and were completely resistant to PrAg -U1 and PrAg -U7 ( shown). Furthermore, the killing of HeLa cells by PrAg -U2 was directly dependent on the concentration of pro-uPA added (Fig. 3) . No cytotoxicity was detected in the absence of prouPA, whereas substantial killing occurred at a pro-uPA concentration of only 12.5 ng/ml (Fig. 3 ).
These data prove that the toxicity of these mutated PrAg proteins to the tumor cells is absolutely dependent on the presence and activation of pro-uPA. Within tissues, the pro-uPA bound to a cell surface uPAR is usually produced by neighboring cells or adsorbed from plasma. Few types of cultured cells produce both cell surface uPAR and secreted pro-uPA. One example is the Lewis lung carcinoma cell line LL3, which produces both proteins (66) (67) (68) (69) . Therefore, it was expected that the LL3 line would be susceptible to PrAg -U2 even in the absence of added prouPA, and this was confirmed in the experiment shown in Fig. 4 . Killing was especially pronounced when exposure to toxin was extended to 48 h.
We next assessed the binding and proteolytic activation of pro-uPA and PrAg -U2 on uPAR-expressing and uPAR non-expressing cells. uPAR-expressing HeLa cells and nonexpressing 293 cells were incubated with 1 µg/ml each of pro-uPA and PrAg -U2 in the absence or presence of plasminogen, PAI-1, and tranexamic acid for various lengths of times. Thereafter, cell lysates and conditioned media were examined by Western blotting to detect the binding and processing of pro-uPA and PrAg -U2. uPAR-expressing HeLa cells proteolytically activated pro-uPA, with active uPA accumulating both on the cell surface and in the medium (Fig. 5A ). In contrast, the uPAR non-expressing 293 cells bound weakly but could not cleave pro-uPA, and only trace amounts of active uPA accumulated in the medium (Fig. 5A) . The activation of prouPA by HeLa cells was completely blocked by PAI-1 (Fig. 5A) , providing further evidence that uPA is activated on the cell surface through a reciprocal activation loop involving pro-uPA and plasminogen. Activation of PrAg -U2 on the HeLa cell surface, determined by the production of (Fig. 5B) , exactly matched the activation profile of pro-uPA on the cell surface (Fig. 5A) . In particular, when the activation of pro-uPA was blocked by PAI-1 (Fig. 5A ), PrAg -U2 activation was blocked in parallel (Fig. 5B) , demonstrating that the activation of PrAg -U2 on the HeLa cell surface required the activation of pro-uPA. As expected, the uPAR non-expressing 293 cells could process neither pro-uPA nor PrAg -U2 (Fig. 5, A and B) . As a control experiment, we
showed that HeLa and 293 cells could process native PrAg (by furin), and this could not be inhibited by PAI-1 (Fig. 5C ). The effect of PAI-1 on cytotoxicity of native PrAg and PrAg -U2
was also assessed. As expected, PAI-1 conferred strong protection to HeLa cells from PrAg -U2 plus FP59, but not from native PrAg plus FP59 (Fig. 6 ).
Although active uPA could also be detected in the conditioned medium of HeLa cells (Fig. 5A) , just a trace amount of PrAg -U2 was activated in the medium (Fig. 5B) , indicating that the coincident binding of PrAg -U2 and uPA on the cell surface facilitated the activation of PrAg -U2 by uPA. To further support this, we also assessed the effects of PrAg-U7, the uncleavable PrAg variant, on the binding and processing of PrAg-U2 by HeLa cells. We showed that PrAg-U2 binding and processing on the HeLa cell surface was completely blocked by the excess amount (200-fold) of PrAg-U7, and the cytotoxicity of PrAg-U2 to HeLa cells was blocked in parallel ( Fig. 7) . In agreement with this, the selective cytotoxicity of PrAg -U2 to uPARexpressing HeLa cells was retained even in a co-culture with the uPAR non-expressing 293 cells, whereas native PrAg killed both cell types (Fig. 8) . The fact that PrAg -U2 activated on HeLa cells did not spillover and cause killing of the bystander 293 cells suggests that the specificity toward tumor cells may be retained in vivo.
The involvement of cell surface-bound plasminogen in the activation of pro-uPA and PrAg -U2 was investigated by the use of tranexamic acid, which inhibits the binding of plasminogen to the cell surface (11, 70) . Pretreatment of cells with 1 mM tranexamic acid strongly inhibited the activation of pro-uPA and PrAg -U2 (Fig. 5, A and B) , but not the activation of native PrAg (data not shown). The involvement of cell surface-bound plasminogen in the cascade activation of pro-uPA and PrAg -U2 was further demonstrated by comparing the effects of two plasmin inhibitors, α 2 -antiplasmin and aprotinin. Aprotinin, which can inhibit the activity of plasmin both on the cell surface and in solution (10, 11) , protected HeLa cells from killing by PrAg -U2 plus FP59. In contrast, α 2 -antiplasmin, which is an inefficient inhibitor of cell surface-bound plasmin (10, 11), could not protect the cells (Fig. 9 ). Aprotinin and α 2 -antiplasmin had no effect on the killing of cells by native PrAg plus FP59 (Fig. 9 ).
We next addressed the role of uPAR in the cytotoxicity of PrAg -U2 to the uPARexpressing HeLa cells by preincubating cells with two reagents that specifically block the binding of uPA to its receptor. ATF, the amino-terminal fragment of uPA, competes with prouPA for binding to uPAR. It protected the tumor cells from killing by PrAg -U2 plus FP59 in a dose-dependent manner, but had no effect on killing by native PrAg plus FP59 (Fig. 10A) .
Similarly, the monoclonal uPAR antibody R3 that specifically blocks the binding of pro-uPA to uPAR also protected the tumor cells from killing by the uPA-activated cytotoxin (Fig. 10B ), but had no effect on the killing of cells by native PrAg. These results demonstrate that the activation of PrAg -U2 and the tumor cell killing was absolutely dependent on the binding of pro-uPA to uPAR. Taken together, we conclude that the cytotoxicity of the uPA-activated PrAg proteins to uPAR-expressing tumor cells was strictly dependent on the integrity of the cell surfaceassociated plasminogen activation system. weakly toxic. Because PrAg -U4 is the mutated PrAg that is most susceptible to cleavage by tPA (Fig. 1C) , we expected it to be toxic to tPA-expressing cells. To test this hypothesis, cytotoxicity assays were performed on two tPA-expressing cells, human Bowes melanoma cells, and primary human umbilical vein endothelial cells (HUVEC). The expression of tPA by these cells was demonstrated by Western blotting of culture supernatants using a polyclonal antibody against human tPA (Fig. 11A) . The cytotoxicity assay was done in serum-free DMEM without addition of pro-uPA and Glu-plasminogen. Different concentrations of native PrAg, PrAg -U2, PrAg -U3, and PrAg -U4 combined with 50 ng/ml FP59 were incubated with cells for 12 h, and cell viability was measured at 48 h. PrAg -U4 was toxic to the two tPA-expressing cells, while
PrAg -U2 and PrAg -U3 showed very low toxicity (Fig. 11 , B and C). The EC 50 values of the PrAg proteins to these tPA-expressing cells are summarized in Table I . These and the above results clearly show that these mutated PrAg proteins, PrAg -U2, PrAg -U3, and PrAg -U4, have differential cytotoxicity to the uPA/uPAR and tPA-expressing cells. We further showed that pro-uPA activated on the uPAR-expressing cell plasma membrane led also to activation of pro-uPA in the supernatant. However, PrAg -U2 was preferentially activated on the cell surface, with only a trace amount being activated in the supernatant. This can be explained as being due to the high affinity binding of PrAg -U2 and uPA to the cell surface, which effectively concentrates them there and results in high local concentrations. Both these receptor-binding events have nanomolar dissociation constants, 0.5 nM for pro-uPA binding to uPAR, and 1 nM for PrAg binding to its as yet unidentified cell surface receptor (76, 77) . These results suggested that the mutated PrAg proteins would be selectively cytotoxic to cells presenting activated uPA on their cell surfaces. This was confirmed by the co-culture experiment in which PrAg -U2 killed only uPAR-expressing HeLa cells while sparing uPAR non-expressing cells.
The results reported here clearly demonstrate that the cytotoxicity of these mutated PrAg proteins is strictly dependent on the tumor cell surface-associated plasminogen activation system, and in particular requires the presence of pro-uPA and its receptor uPAR on the tumor cell surface. Thus, these mutated PrAg proteins can be expected to target tumor tissues that overexpress both these factors. These results encourage the further testing of PrAg -U2 and PrAg -U3 in animal tumor models. The tPA-specific mutated PrAg protein, PrAg -U4, may be useful for targeting of tumors overexpressing tPA, such as melanomas (78, 79) , although the activation of PrAg -U4 by vascular endothelial cells warrants caution.
Many tumor-cell selective cytotoxins have been created by replacing the receptor- containing 2 mg/ml BSA, 1 µg/ml Glu-plasminogen, 1 µg/ml pro-uPA, with 1 µg/ml PrAg-U2
and 50 ng/ml FP59 or 1 µg/ml PrAg-U2, 200 µg/ml PrAg-U7 and 50 ng/ml FP59 at 37 o C. After 2-h incubation, the cells were washed, and the cell lysates were analyzed by Western blotting by using a rabbit anti-PrAg polyclonal antibody (#5308) (in panel A). For the cytotoxicity assay (in panel B), the toxins were removed and replaced with fresh serum-containing DMEM after 6 h.
MTT was added to determine cell viability at 48 h. HeLa cells were cultured to 50% confluence and preincubated with serum-free DMEM containing 100 ng/ml of pro-uPA and 1 µg/ml of Glu-plasminogen with or without 40 µg/ml α 2 -antiplasmin or 100 µg/ml aprotinin for 30 min. Then 300 ng/ml PrAg or PrAg -U2 combined with 50 ng/ml FP59 were added to the cells for 6 h. The toxins were removed and replaced with fresh serum-containing DMEM. MTT was added to determine cell viability at 48 h. The analysis was performed two additional times with similar results. (Mean ±S.D., n=2). PrAg-U2 (ng/ml) Viability (% of control) pro-uPA 200 ng/ml pro-uPA 100 ng/ml pro-uPA 50 ng/ml pro-uPA 25 ng/ml pro-uPA 12.5 ng/ml pro-uPA 6.2 ng/ml pro-uPA 3.1 ng/ml pro-uPA 1.6 ng/ml pro-uPA 0.8 ng/ml pro-uPA 0.0 ng/ml 
